FDA calendar · February 2024 · built from SEC filings

PDUFA dates February 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

2 PDUFA dates fell in February 2024: Amtagvi® (February 24), roluperidone (February 26). The FDA calendar also recorded 38 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in February 2024

2 PDUFA target action dates in February 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
February 24, 2024IOVANCE BIOTHERAPEUTICS, INC.IOVAAmtagvi® (lifileucel)SEC 8-K Exhibit 99.1, filed 2025-08-07
February 26, 2024Minerva Neurosciences, Inc.NERVroluperidone (MIN-101)SEC Form 10-Q, filed 2025-08-14

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

February 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Feb 2024Month disclosedbiosimilarALVOFDA approval—ApprovedSEC Form 10-K
Feb 2024Month disclosedAMJEVITA® (adalimumab)ALVOFDA approval—ApprovedSEC 8-K Exhibit 99.1
February 1, 2024Cefazolin In Dextrose (cefazolin sodium)BAXLabel expansion—ApprovedopenFDA Drugs@FDA
Feb 2024Month disclosedCMND-100CMNDFDA approval—ApprovedSEC 8-K Exhibit 99.1
Feb 2024Month disclosedvascularHUMANDA/BLA accepted—CompletedSEC 8-K Exhibit 99.1
Feb 2024Month disclosedenekinragene inzadenovec (PCRX-201)PCRXFDA approval—ApprovedSEC Form 10-Q
February 9, 2024Eohilia (budesonide)TAKFDA approval—ApprovedopenFDA Drugs@FDA
February 9, 2024Gvoke Kit (glucagon)XERSComplete Response Letter—CRL issuedFDA Complete Response Letters
February 14, 2024Protonix Iv (pantoprazole sodium)BAXFDA approval—ApprovedopenFDA Drugs@FDA
February 16, 2024Tagrisso® (osimertinib)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
February 16, 2024Amtagvi® (lifileucel)IOVAFDA approvalwith post-anti-PD-1 advanced melanomaApprovedSEC 8-K Exhibit 99.1
February 20, 2024Tecvayli (teclistamab-cqyv)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
February 23, 2024Simlandi (adalimumab-ryvk)ALVOFDA approval—ApprovedopenFDA Drugs@FDA
February 23, 2024Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
February 24, 2024biosimilarALVONDA/BLA accepted—Completedsec_424b
February 24, 2024SIMLANDI®TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
February 24, 2024AMJEVITA® (adalimumab)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
February 26, 2024roluperidone (MIN-101)NERVComplete Response Letternegative symptoms in patients with schizophreniaCRL issuedsec_424b
February 26, 2024ReleaseNERVComplete Response Letter—CRL issuedFDA Complete Response Letters
February 28, 2024Veklury (remdesivir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA

February 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
Feb 2024Month disclosedapraglutideIRWDTopline readout—PositiveSEC Form 10-Q
Feb 2024Month disclosednomlabofusp (CTI-1601)LRMRTopline readout—PositiveSEC Form 10-Q
Feb 2024Month disclosedRT-111RANITopline readoutinflammatory conditionsPositiveSEC Form 10-K
Feb 2024Month disclosedallergies (EPI-17)SPRYTopline readout—Met primary endpointSEC Form 10-Q
Feb 2024Month disclosed—TARSTopline readoutocular rosaceaPositiveSEC Form 10-Q
Feb 2024Month disclosed—TARSTopline readoutrosaceaPositiveSEC Form 10-Q
Feb 2024Month disclosed—TARSTopline readoutrosaceaPositiveSEC Form 10-Q
Feb 2024Month disclosedVK2735VKTXTopline readoutobesity, in June 2025, wePositiveSEC Form 10-Q

February 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Feb 2024Month disclosedolverembatinib (HQP1351)AAPGTrial start—CompletedSEC 8-K Exhibit 99.1
Feb 2024Month disclosedalisertib (PB-8237)PBYITrial startwith extensive-stage small cell lung cancerCompletedSEC 8-K Exhibit 99.1
Feb 2024Month disclosedDNL126DNLITrial start—CompletedSEC Form 10-K
Feb 2024Month disclosedABS-101ABSITrial start—CompletedSEC Form 10-Q
Feb 2024Month disclosedKB408KRYSTrial startwith AATDCompletedSEC Form 10-Q
Feb 2024Month disclosedMNPR-101MNPRTrial startadvanced cancers, and in April 2024, we launched the Phase 1 trialCompletedSEC Form 10-Q
February 13, 2024CB-012CRBUTrial start—CompletedSEC Form 10-K
Feb 2024Month disclosedAPHEXDA® (motixafortide)BLRXTrial start—CompletedSEC 8-K Exhibit 99.1
February 15, 2024FOLOTYNCASIFTrial start—CompletedSEC 8-K Exhibit 99.1
February 26, 2024KOMET-008KURATrial start—CompletedSEC Form 10-K

2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps February 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in February 2024?

2 PDUFA dates fell in February 2024: Amtagvi® (February 24), roluperidone (February 26). The FDA calendar also recorded 38 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.